Avacta Group PLC Notice of Results (4814L)
06 September 2023 - 4:00PM
UK Regulatory
TIDMAVCT
RNS Number : 4814L
Avacta Group PLC
06 September 2023
6 September 2023
Avacta Group plc
("Avacta" or the "Company" and, together with its subsidiary
undertakings, the "Group")
Notice of Results
Investor Presentation via Investor Meet Company
Avacta Group plc (AIM: AVCT), a life sciences company developing
innovative, targeted oncology drugs and powerful diagnostics, will
announce its unaudited interim results for the six months ended 30
June 2023 on Thursday 28 September 2023.
Alistair Smith, CEO and Tony Gardiner, CFO will provide a live
presentation via Investor Meet Company on Thursday 28 September
2023 at 11:00am BST.
The presentation is open to all existing and potential
shareholders. Questions can be submitted pre-event via your
Investor Meet Company dashboard up until 9:00am BST the day before
the meeting.
Investors can sign up to Investor Meet Company for free and add
to meet AVACTA GROUP PLC via:
https://www.investormeetcompany.com/avacta-group-plc/register-investor
.
Investors who already follow Avacta on the Investor Meet Company
platform will automatically be invited.
The Company will also post its results presentation on its
website at the following page:
https://avacta.com/investors/documents-presentations .
-Ends-
For further information from Avacta Group plc, please
contact:
Avacta Group plc Tel: +44 (0) 1904 21 7070
Alastair Smith, Chief Executive www.avacta.com
Officer
Tony Gardiner, Chief Financial
Officer
Michael Vinegrad, Group Communications
Director
Stifel Nicolaus Europe Limited Tel: +44 (0) 207 710 7600
(Nomad and Broker) www.stifel.com
Nicholas Moore / Nick Adams /
Samira Essebiyea / Nick Harland
/ Dhiren Suares / William Palmer-Brown
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson mailto:cscavacta@consilium-comms.com
/ Sukaina Virji avacta@consilium-comms.com
About Avacta Group plc - www.avacta.com
Avacta Group plc is a life sciences company working to improve
people's health and well-being through innovative oncology drugs
and powerful diagnostics. Operating through two divisions,
Diagnostics and Therapeutics, the Group's mission is to provide
professionals and consumers with solutions that improve healthcare,
fitness and well-being.
Avacta's Therapeutics Division, a clinical stage oncology drug
innovator, is building a wholly owned pipeline of novel Affimer(R)
immunotherapies and pre|CISION(TM) tumour targeted chemotherapies.
This approach is designed to address the lack of a durable response
to current cancer immunotherapies experienced by most patients and
reduce the severe systemic toxicities caused by chemotherapies.
There are five programmes in the pipeline as well as several global
research collaborations and licensing partnerships. Avacta's lead
programme, AVA6000, is a pre|CISION(TM) tumour-targeted form of the
established chemotherapy doxorubicin. AVA6000 is in Phase I
clinical trials in patients with locally advanced or metastatic
selected solid tumours.
The Affimer(R) platform is an alternative to antibodies that has
been designed to address many of the drawbacks of antibodies which,
despite their shortcomings, currently dominate the
immuno-diagnostics and immuno-therapeutics markets.
The pre|CISION(TM) tumour targeting platform can be used to
modify a chemotherapy in order to selectively release the active
drug in tumour tissue thereby reducing the systemic exposure that
causes damage to healthy tissues. pre|CISION(TM) modified
chemotherapies are designed to reduce the side effects and improve
the overall safety and therapeutic potential of these powerful
anti-cancer treatments.
Avacta's Diagnostics Division develops and supplies a broad
range of in-vitro diagnostic (IVD) solutions. The Division is
growing rapidly through an M&A strategy to deliver a
global-scale IVD business providing market-leading solutions for
healthcare professionals and consumers to inform treatment and
monitor health and well-being. In October 2022, Avacta acquired
Launch Diagnostics which serves the hospital pathology laboratory
market in the UK and Europe. In May 2023, Avacta acquired Coris
Bioconcept a Belgium-based lateral flow test developer and
manufacturer adding a broad range of marketed professional-use
rapid tests into the Diagnostics Division. Avacta Diagnostic's
research and development centre in Wetherby, UK uses its
proprietary Affimer(R) platform to differentiate immunodiagnostic
products to provide market-leading performance.
To register for news alerts by email go to
www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSSIFAIEDSELU
(END) Dow Jones Newswires
September 06, 2023 02:00 ET (06:00 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024